Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30516909 | 1.00 | HPRT1 (0.52) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL29442976 | 0.90 | ALDH1A1 (0.44) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL4623560 | 0.90 | ALDH1A1 (0.44) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| Lithium SCHEMBL29767624 | 0.89 | ALDH1A1 (0.42) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL30516914 | 0.86 | HPRT1 (0.36) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL3414799 | 0.82 | HPRT1 (0.48) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL30516919 | 0.82 | HPRT1 (0.48) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL30996901 | 0.82 | HPRT1 (0.48) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL4623032 | 0.81 | HSD17B10 (0.39) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL30329701 | 0.81 | HPRT1 (0.47) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160738-B2 | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors | WASHINGTON UNIVERSITY (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180086727-A9 | NEUROACTIVE SUBSTITUTED CYCLOPENT[a]ANTHRACENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| US-20170233356-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENT[a]ANTHRACENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | UNIV WASHINGTON (US) | 2017-08-17 | — | — | US | disclosed |
| US-9562026-B2 | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors | WASHINGTON UNIVERSITY (US) | 2017-02-07 | — | — | US | disclosed |
| US-20140275241-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENT[a]ANTHRACENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-18 | — | — | US | disclosed |
| US-7906710-B2 | Transgenic plants containing altered levels of steroid compounds | MONSANTO COMPANY (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100037354-A1 | TRANSGENIC PLANTS CONTAINING ALTERED LEVELS OF STEROID COMPOUNDS | KARUNANANDAA BALASULOJINI | 2010-02-11 | — | — | US | disclosed |
| US-7544863-B2 | Transgenic plants containing altered levels of steroid compounds | MONSANTO TECHNOLOGY LLC (US) | 2009-06-09 | — | — | US | disclosed |
| US-7470290-B2 | Hydroscopic polymer gels for easier cleaning | THE CLOROX COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| WO-2007096134-A1 | LIPIDATED OLIGONUCLEOTIDES | HUMBOLDT-UNIVERSITÄT ZU BERLIN (DE) | 2007-08-30 | — | — | WO | disclosed |
| EP-1381267-A2 | TRANSGENIC PLANTS CONTAINING ALTERED LEVELS OF STEROID COMPOUNDS | Monsanto Technology LLC (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20030150008-A1 | Transgenic plants containing altered levels of steroid compounds | MONSANTO TECHNOLOGY, L.L.C. | 2003-08-07 | — | — | US | disclosed |
| WO-2002061072-A2 | TRANSGENIC PLANTS CONTAINING ALTERED LEVELS OF STEROID COMPOUNDS | MONSANTO TECHNOLOGY LLC (US) | 2002-08-08 | — | — | WO | disclosed |
| US-6399796-B2 | ISOLATION FROM A STEROL MIXTURE BY EXOGENOUSLY PROVIDING A CATALYTIC AMOUNT OF AN UNSATURATED C12-C24 CARBOXYLIC FATTY ACID TO THE REACTION OF THE STEROLDIENE AND A DIENOPHILE | ROCHE VITAMINS INC. | 2002-06-04 | — | — | US | disclosed |
| EP-0991674-B1 | CYCLOPENTA[I]PHENANTHRENE METAL COMPLEX CATALYST SYSTEMS | BASF AG (DE) | 2002-04-03 | — | — | EP | disclosed |
| US-20010047093-A1 | Activation of a diels-alder reaction of a sterol 5,7 diene | MONSANTO TECHNOLOGY LLC (US) | 2001-11-29 | — | — | US | disclosed |
| US-6310256-B1 | REDUCING 1-CARBOHYDROCARBYLOXY-2-KETO-4-HYDROXY-5-CYCLOPENTENE COMPOUND BY CONTACTING WITH ZINC AND DECARBOXYLATING THE RESULTING REACTION PRODUCT BY CONTACTING THE REACTION MIXTURE WITH A MIXTURE OF AN ORGANIC ACID AND INORGANIC HALIDE | THE DOW CHEMICAL COMPANY | 2001-10-30 | — | — | US | disclosed |
| US-6284851-B1 | Cyclopenta[I] phenanthrene-metal complex catalyst systems | BASF AKTIENGESELLSCHAFT (DE) | 2001-09-04 | — | — | US | disclosed |
| US-6258902-B1 | USING A METAL COMPLEX CATALYST AND AN ALKENYL CONTAINING HYDROCARBYLSILANE | THE DOW CHEMICAL COMPANY | 2001-07-10 | — | — | US | disclosed |
| EP-0486290-A2 | A method and composition for increasing the accumulation of squalene and specific sterols in yeast | AMOCO CORPORATION (US) | 1992-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030150008-A1 | Transgenic plants containing altered levels of steroid compounds | HMGCR, CYP11A1, CYP46A1 | HPRT1 1557/4885ALDH1A1 1324/4885HSD17B10 28/4885 |
| US-20140275241-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENT[a]ANTHRACENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | GABRA4, GABRA2, GABRA6 | HPRT1 3198/4885ALDH1A1 384/4885HSD17B10 1096/4885 |
| US-20170233356-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENT[a]ANTHRACENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | GABRA4, GABRA2, GABRA6 | HPRT1 3198/4885ALDH1A1 384/4885HSD17B10 1096/4885 |
| US-10160738-B2 | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors | GABRA4, GABRA2, GABRA6 | HPRT1 3198/4885ALDH1A1 384/4885HSD17B10 1096/4885 |
| US-20180086727-A9 | NEUROACTIVE SUBSTITUTED CYCLOPENT[a]ANTHRACENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | GABRA4, GABRA2, GABRA6 | HPRT1 3198/4885ALDH1A1 384/4885HSD17B10 1096/4885 |
| US-20010047093-A1 | Activation of a diels-alder reaction of a sterol 5,7 diene | DHCR7, SCD5, CYP11A1 | HPRT1 4719/4885ALDH1A1 499/4885HSD17B10 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.